TAX 3501: A multicenter, open-label, randomized, PhaseIII Trial comparing immediate Adjuvant Hormonal Therapy (ELIGARD - leuprolide acetate) in combination with TAXOTERE (docetacel) administered every three weeks versus hormonal therapy alone versus deferred therapy followed by the same therapeutic options in patients with prostate cancer at high risk of relapse after radical prostatectomy AUO-Studie
Laufzeit: 01.01.2006 - 31.12.2011
